Table 3. Open in new tab Emergent Drug...

Table 3.

Emergent Drug Resistance Mutations in UL97

Study Drug	Amino Acid Substitution	n^a	Maribavir EC₅₀ Ratio^b	Ganciclovir EC₅₀ Ratio^b	Reference for EC₅₀
Maribavir	G343A	1	126	8.5	Table 4
Maribavir	T409M	19	80	1.3	[11]
Maribavir	H411Y	12	17	0.7	[11]
Maribavir	C480F	1	210	2.3	[11]
Valganciclovir	M460I	1	0.21	12	[11]
Valganciclovir	M460V	1	0.30	9.1	[11]
Valganciclovir	H520Q	1	0.66	9.7	[11]
Valganciclovir	A594P	1	1.6	7.9	[11]
Valganciclovir	A594V	2	1.9	6.9	[11]
Valganciclovir	C603W	1	1.2	5.9	[11]

Study Drug	Amino Acid Substitution	n^a	Maribavir EC₅₀ Ratio^b	Ganciclovir EC₅₀ Ratio^b	Reference for EC₅₀
Maribavir	G343A	1	126	8.5	Table 4
Maribavir	T409M	19	80	1.3	[11]
Maribavir	H411Y	12	17	0.7	[11]
Maribavir	C480F	1	210	2.3	[11]
Valganciclovir	M460I	1	0.21	12	[11]
Valganciclovir	M460V	1	0.30	9.1	[11]
Valganciclovir	H520Q	1	0.66	9.7	[11]
Valganciclovir	A594P	1	1.6	7.9	[11]
Valganciclovir	A594V	2	1.9	6.9	[11]
Valganciclovir	C603W	1	1.2	5.9	[11]

EC₅₀ ratios ≥2.0 are shown in bold, ratios ≤0.5 are in italic.

Abbreviation: EC₅₀, drug concentration that reduces viral growth by 50%.

^aNumber of patients developing indicated amino acid substitution.

^bEC₅₀ of mutant virus/EC₅₀ of wild-type control strain.